Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kay W Chang

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Cancer|October 9, 2009
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology GroupHoward M Katzenstein, Kay W Chang, Mark Krailo, et al.
Cancer Medicine|May 31, 2018
Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trialsLori M Minasian, A Lindsay Frazier, Lillian Sung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood CancerJohnnie K Bass, Chia-Ho Hua, Jie Huang, et al.
The Lancet. Child & Adolescent Health|December 24, 2019
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guidelineDavid R Freyer, Penelope R Brock, Kay W Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scalePenelope R Brock, Kristin R Knight, David R Freyer, et al.
Cancer|July 7, 2005
Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group studyNeyssa Marina, Kay W Chang, Marcio Malogolowkin, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|May 19, 2026
Beta-2 Transferrin May Not Be Specific for Presence of Cerebrospinal Fluid in Middle Ear FluidAnthony Thai, Sasa Vasilijic, Lindsay S Moore, et al.
Pediatric Blood & Cancer|February 8, 2014
Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastomaJohnnie K Bass, Jie Huang, Arzu Onar-Thomas, et al.
Pediatric Blood & Cancer|March 24, 2025
Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical TrialDavid R Freyer, Timothy J D Ohlsen, Debra Don, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|December 19, 2019
International Pediatric Otolaryngology Group (IPOG) Consensus Recommendations: Congenital CholesteatomaFrançoise Denoyelle, François Simon, Kay W Chang, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Cancer|October 9, 2009
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology GroupHoward M Katzenstein, Kay W Chang, Mark Krailo, et al.
Cancer Medicine|May 31, 2018
Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trialsLori M Minasian, A Lindsay Frazier, Lillian Sung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood CancerJohnnie K Bass, Chia-Ho Hua, Jie Huang, et al.
The Lancet. Child & Adolescent Health|December 24, 2019
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guidelineDavid R Freyer, Penelope R Brock, Kay W Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scalePenelope R Brock, Kristin R Knight, David R Freyer, et al.
Cancer|July 7, 2005
Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group studyNeyssa Marina, Kay W Chang, Marcio Malogolowkin, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|May 19, 2026
Beta-2 Transferrin May Not Be Specific for Presence of Cerebrospinal Fluid in Middle Ear FluidAnthony Thai, Sasa Vasilijic, Lindsay S Moore, et al.
Pediatric Blood & Cancer|February 8, 2014
Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastomaJohnnie K Bass, Jie Huang, Arzu Onar-Thomas, et al.
Pediatric Blood & Cancer|March 24, 2025
Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical TrialDavid R Freyer, Timothy J D Ohlsen, Debra Don, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|December 19, 2019
International Pediatric Otolaryngology Group (IPOG) Consensus Recommendations: Congenital CholesteatomaFrançoise Denoyelle, François Simon, Kay W Chang, et al.
Pageof 7